Hypomethylating Agents for AML

preview_player
Показать описание
Naval Daver, MD, looks at the use of decitabine and azacitidine in patients with p53-mutated acute myeloid leukemia and the optimal duration of therapy in patients who are unfit for intensive chemotherapy.

Рекомендации по теме